Clinical Trials Browser

Interventional × Neoplasm Metastasis × budigalimab × Clear all

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03821935 2025-05-25

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

364 enrolled

BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06119217 2024-12-04

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Phase 2 Active not recruiting

194 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Clinical Trials

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients